Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1.079 INR | -0,09% | +5,16% | +26,39% |
25/04 | L'utile netto di Glenmark Lifesciences scende nel quarto trimestre fiscale | MT |
01/04 | Glenmark Pharmaceuticals Limited annuncia cambiamenti nel Consiglio d'Amministrazione | CI |
Attività
Numero di dipendenti: 15 556
Vendite per attività
INR in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100,0
%
| 123 049 | 100,0 % | 129 901 | 100,0 % | +5,57% |
Vendite per regione
INR in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
India
34,4
%
| 43 809 | 35,6 % | 44 675 | 34,4 % | +1,98% |
North America
25,0
%
| 32 035 | 26,0 % | 32 484 | 25,0 % | +1,40% |
Europe
17,7
%
| 20 047 | 16,3 % | 23 047 | 17,7 % | +14,97% |
Rest of the World
17,3
%
| 21 031 | 17,1 % | 22 414 | 17,3 % | +6,58% |
Latin America
5,6
%
| 6 127 | 5,0 % | 7 281 | 5,6 % | +18,83% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 12/10/98 | |
Ulhas Dhuppad
PSD | President | - | - |
Alind Sharma
PSD | President | - | 01/06/22 |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 16/11/17 |
Nikhil Amin
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | - | |
Harish Kuber
CMP | Compliance Officer | - | 02/02/17 |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 01/01/83 |
Cherylann Pinto
BRD | Director/Board Member | 56 | 06/10/99 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 59 | 14/08/20 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 06/10/99 |
Chief Executive Officer | 54 | 12/10/98 | |
Rajesh V. Desai
BRD | Director/Board Member | 65 | 01/01/83 |
Director/Board Member | 83 | 14/08/09 | |
Director/Board Member | 68 | 10/02/23 | |
Director/Board Member | 48 | 01/04/19 | |
V. S. Mani
DFI | Director of Finance/CFO | 59 | 16/11/17 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 282 188 156 | 138 368 096 ( 49,03 %) | 0 | 49,03 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
9 609 571 | 7.84% | 89 329 419 $ |
Coordinate società
Glenmark Pharmaceuticals Ltd.
Glenmark House Off Western Express Highway
400099, Mumbai
+91 22 4018 9999
http://www.glenmarkpharma.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Glenmark Pharmaceuticals USA, Inc. manufactures, markets, and distributes generic pharmaceutical products. It offers campral delayed-release tablets, differin gel, aclovate cream, aclovate topical ointment, ortho novum, and other related products. The company was founded in 2003 and is headquartered in Mahwah, NJ. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Settore
Vendite per regione
Revisioni EPS
Fatturato trimestrale - Indice di sorpresa
Variaz. 1 gen. | Capi. | |
---|---|---|
+26,39% | 3,65 Mrd | |
+19,62% | 43,34 Mrd | |
+20,44% | 21,96 Mrd | |
+10,86% | 14,09 Mrd | |
+13,07% | 13,64 Mrd | |
+37,46% | 11,43 Mrd | |
-8,59% | 6,86 Mrd | |
-0,05% | 6,79 Mrd | |
-8,87% | 5,73 Mrd | |
+8,46% | 5,22 Mrd |
- Borsa valori
- Azioni
- Azione GLENMARK
- Società Glenmark Pharmaceuticals Limited